Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry

Bernardo Cortese, Luca Testa, Gaetano Di Palma, Tay M. Heang, Irene Bossi, Amin A. Nuruddin, Alfonso Ielasi, Maurizio Tespili, Ignacio S. Perez, Diego Milazzo, Susanna Benincasa, Azeem Latib, Michele Cacucci, Gianluca Caiazzo, Giuseppe Seresini, Fabrizio Tomai, Raymundo Ocaranza, Alfonso Torres, Anna Perotto, Francesco BedogniAntonio Colombo

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

AIMS: The purpose of the EASTBOURNE registry is to evaluate the immediate and long-term clinical performance of a novel sirolimus-coated balloon (SCB) in a real-world population of patients with coronary artery disease. We here present the prespecified interim analysis after the enrollment of the first 642 patients who obtained 1-year clinical follow-up. METHODS: EASTBOURNE is a prospective, international, multicenter, all-comer investigator-driven clinical registry, which is enrolling consecutive patients treated with SCB at 42 European and Asiatic centers. Primary study endpoint is target-lesion revascularization (TLR) at 12 months. Secondary endpoints are procedural success and major adverse cardiac events through 36 months. RESULTS: Diabetes mellitus was present in 41% of patients. Acute coronary syndrome was present in 45% of patients and de novo lesions were 55%; 83% of the in-stent restenosis (ISR) patients had drug-eluting stents restenosis. Lesion predilatation was performed in 95% of the cases and bailout stenting occurred in 7.5%. So far, 642 patients have a complete 12-month follow-up. TLR occurred in 2.5%, myocardial infarction in 2.3%, total death in 1% and major adverse cardiac events in 5.8% of patients. A prespecified analysis of comparison between ISR and de-novo lesions showed a significantly higher occurrence of TLR in the ISR population (5.4 vs. 0.2%, P = 0.0008). CONCLUSION: The current interim analysis of 12-month follow-up of the EASTBOURNE registry shows good immediate performance and an adequate and encouraging safety profile through 12 months for this novel SCB.

Original languageEnglish (US)
Pages (from-to)94-100
Number of pages7
JournalJournal of Cardiovascular Medicine
Volume22
Issue number2
DOIs
StatePublished - Feb 1 2021
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Clinical performance of a novel sirolimus-coated balloon in coronary artery disease: EASTBOURNE registry'. Together they form a unique fingerprint.

Cite this